Search Results

You are looking at 81 - 90 of 131 items for :

  • "symptom burden" x
  • Refine by Access: All x
Clear All
Full access

A Pilot Study of a Comprehensive Financial Navigation Program in Patients With Cancer and Caregivers

Kate Watabayashi, Jordan Steelquist, Karen A. Overstreet, Anthony Leahy, Erin Bradshaw, Kathleen D. Gallagher, Alan J. Balch, Rebecca Lobb, Laura Lavell, Hannah Linden, Scott D. Ramsey, and Veena Shankaran

; 32 : 306 – 311 . 10.1200/JCO.2013.52.9123 24366936 2. Lathan CS , Cronin A , Tucker-Seeley R , . Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer . J Clin Oncol 2016 ; 34

Full access

Loneliness and Mortality Risk Among Cancer Survivors in the United States: A Retrospective, Longitudinal Study

Jingxuan Zhao, Jennifer B. Reese, Xuesong Han, and K. Robin Yabroff

and symptom burden in oncology patients during the COVID-19 pandemic . Cancer 2021 ; 127 : 3246 – 3253 . 43. Hawkley LC , Cacioppo JT . Loneliness matters: a theoretical and empirical review of consequences and mechanisms . Ann Behave Med

Full access

Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

Peter G. Shields, Roy S. Herbst, Douglas Arenberg, Neal L. Benowitz, Laura Bierut, Julie Bylund Luckart, Paul Cinciripini, Bradley Collins, Sean David, James Davis, Brian Hitsman, Andrew Hyland, Margaret Lang, Scott Leischow, Elyse R. Park, W. Thomas Purcell, Jill Selzle, Andrea Silber, Sharon Spencer, Tawee Tanvetyanon, Brian Tiep, Hilary A. Tindle, Reginald Tucker-Seeley, James Urbanic, Monica Webb Hooper, Benny Weksler, C. Will Whitlock, Douglas E. Wood, Jennifer Burns, and Jillian Scavone

, chemotherapy metabolism and side effects, and overall symptom burden. This discussion also addresses the developing evidence base for the benefits of smoking cessation after receiving a cancer diagnosis. Smoking-Associated Risks: Surgery: Smoking has been

Full access

Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management

Prithviraj Bose and Srdan Verstovsek

-risk patients with PV is usually achieved with phlebotomy alone. However, patients with PV and ET, especially the former, can have a substantial symptom burden. 23 , 34 – 36 In the RESPONSE trial, which led to the recent approval of ruxolitinib for the

Full access

Palliative Care

Michael H. Levy, Michael D. Adolph, Anthony Back, Susan Block, Shirley N. Codada, Shalini Dalal, Teresa L. Deshields, Elisabeth Dexter, Sydney M. Dy, Sara J. Knight, Sumathi Misra, Christine S. Ritchie, Todd M. Sauer, Thomas Smith, David Spiegel, Linda Sutton, Robert M. Taylor, Jennifer Temel, Jay Thomas, Roma Tickoo, Susan G. Urba, Jamie H. Von Roenn, Joseph L. Weems, Sharon M. Weinstein, Deborah A. Freedman-Cass, and Mary Anne Bergman

the course of illness for patients with metastatic cancer and/or high symptom burden. A remarkable recent study showed that early introduction of palliative care can not only improve quality of life for patients with advanced cancer but also improve

Full access

Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma

Adam J. Olszewski, Kalyan C. Mantripragada, and Jorge J. Castillo

. This approach does not require complex clinical assessments, which in DLBCL may reflect symptom burden rather than baseline functional reserve. The identified predictors of early death fall into 3 domains related to the lymphoma (B symptoms

Full access

Using the Science of Psychosocial Care to Implement the New American College of Surgeons Commission on Cancer Distress Screening Standard

Lynne I. Wagner, David Spiegel, and Timothy Pearman

rating, similar to a pain assessment, and can assess the source of distress (eg, symptom burden, financial concerns) when present. Clinicians could administer a semistructured screening questionnaire, such as the Primary Care Evaluation of Mental

Full access

Hematopoietic Stem Cell Transplantation for Older Patients With Myelodysplastic Syndromes

H. Joachim Deeg and Marcos de Lima

both recurrent disease and GVHD, frequently associated with a significant symptom burden. The presence of GVHD is generally considered a contraindication for the infusion of donor lymphocytes, one of the modalities used to treat post-HCT relapse

Full access

External Validation of Risk Factors for Unplanned Hospitalization in Older Adults With Advanced Cancer Receiving Chemotherapy

Mostafa R. Mohamed, Kah Poh Loh, Supriya G. Mohile, Michael Sohn, Tracy Webb, Megan Wells, Sule Yilmaz, Rachael Tylock, Eva Culakova, Allison Magnuson, Can-Lan Sun, James Bearden, Judith O. Hopkins, Bryan A. Faller, and Heidi D. Klepin

. 32879429 20. Lage DE , El-Jawahri A , Fuh CX , Functional impairment, symptom burden, and clinical outcomes among hospitalized patients with advanced cancer . J Natl Compr Canc Netw 2020 ; 18 : 747 – 754 . 32502982 21. Arrieta O

Full access

Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy

Justine Lequesne, Florence Joly, Julien Peron, Isabelle Ray-Coquard, Anne-Claire Hardy-Bessard, Frédéric Selle, Dominique Berton, Philippe Follana, Michel Fabbro, Alain Lortholary, Eric Pujade-Lauraine, Sophie Lefèvre-Arbogast, and Elodie Coquan

low-/moderate-grade AEs. 15 , 19 References 1. Lee YC , King MT , O’Connell RL , Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study